Harrow's record Q3 revenue meets a halved EBITDA outlook, as Q4 must carry the year
Branded sales drove 39% year-over-year growth, but Harrow cut full-year Adjusted EBITDA guidance to more than $40 million and now needs a steep fourth quarter to hit revenue targets.
The quarter in numbers
Harrow reported record third-quarter revenue of $99.3 million, up 41% sequentially and 39% from $71.6 million a year earlier. Branded products brought in $83.5 million, up 62% year over year and about 84% of the total.
Gross margin was 75%, unchanged from the third quarter of 2025. GAAP net income was $9.8 million ($0.25 per diluted share), against a $1.0 million profit a year ago and a $17.3 million net loss in the second quarter of 2026. The company said the quarter included a $5.0 million litigation settlement gain.
Adjusted EBITDA, a non-GAAP measure, was $21.2 million. That is a sharp recovery from $(1.2) million in the second quarter but slightly below the $22.8 million of the third quarter of 2025.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Sources
- Harrow, Inc.: quarterly results release (SEC filing) SEC EDGAR · 09 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.
Tonix's TONMYA reaches $15M, but a $163M cash pile and a Paragraph IV filing frame the debate
Third-quarter net product revenue rose to about $17.2M, yet opex of $72.7M and a runway only into early Q3 2027 mean financing and patent litigation loom over the launch.
ADC Therapeutics: volume-led sales and deeper cost cuts, as recapitalisation shifts focus to ASH
Q3 net product revenue of $21.0M and a 29% cut in adjusted opex narrowed the loss, while an October restructuring extended the company's expected cash runway into 2029.
Inhibrx's Q3: Debt and launch prep push losses up as chondrosarcoma review looms
A $2.0 million Pfizer licence fee barely dented a $38.7 million net loss as interest costs and pre-commercial spend rose while R&D fell and the balance sheet moved into deficit.